Most Recent
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
Acciona is mulling a bid to summarily dismiss a "hopelessly flawed" patent suit by its construction partner on the troubled East Rockingham waste-to-energy plant project, saying it is doomed in light of a High Court decision holding a patentee’s rights are exhausted at the time of sale.